RHPRG4
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for RHPRG4, covering 2025-09-29 to 2026-02-05. Get the full timeline:
Most recent: Clinical Trial Update: A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE [Phase 2]